Raleigh Capital Management’s Pfizer PFE Stock Holding History

Raleigh Capital Management’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.76M	Buy	114,644 +13,199	+13%	+$345K	0.88%	24
2026 Q1	$2.85M	Buy	101,445 +72	+0.1%	+$1.92K	0.98%	23
2025 Q4	$2.52M	Buy	101,373 +7,330	+8%	+$185K	0.92%	26
2025 Q3	$2.4M	Buy	94,043 +16,211	+21%	+$400K	0.91%	27
2025 Q2	$1.89M	Buy	77,832 +14,824	+24%	+$346K	0.79%	37
2025 Q1	$1.6M	Buy	63,008 +4,881	+8%	+$128K	0.72%	47
2024 Q4	$1.54M	Sell	58,127 -2,205	-4%	-$59.8K	0.59%	51
2024 Q3	$1.75M	Sell	60,332 -1,496	-2%	-$43.6K	0.67%	37
2024 Q2	$1.73M	Sell	61,828 -8,928	-13%	-$246K	0.74%	35
2024 Q1	$1.96M	Buy	70,756 +6,275	+10%	+$174K	0.85%	31
2023 Q4	$1.86M	Sell	64,481 -2,270	-3%	-$68.6K	0.86%	30
2023 Q3	$2.21M	Buy	66,751 +1,484	+2%	+$52.5K	1.13%	19
2023 Q2	$2.39M	Buy	65,267 +2,927	+5%	+$114K	1.19%	15
2023 Q1	$2.54M	Buy	62,340 +11,800	+23%	+$510K	1.26%	17
2022 Q4	$2.59M	Buy	50,540 +8,539	+20%	+$409K	1.35%	16
2022 Q3	$1.84M	Buy	42,001 +6,830	+19%	+$332K	1.07%	24
2022 Q2	$1.84M	Buy	35,171 +3,252	+10%	+$166K	1.05%	24
2022 Q1	$1.65M	Buy	31,919 +31,537	+8,256%	+$1.64M	0.9%	25
2021 Q4	$23K	Buy	+382	New	+$18.9K	0.02%	162

Other funds holding PFE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Raleigh Capital Management's PFE Position: Q2 2026 in Review

Raleigh Capital Management increased its Pfizer (PFE) stake by 13% in Q2 2026, buying an estimated $345K and bringing the position to 114,644 shares worth $2.76M. The position accounts for 0.88% of the portfolio, ranked #24.

Raleigh Capital Management first reported a position in PFE in Q4 2021 and has held it in 19 quarters since. The position peaked at $2.85M in Q1 2026. 2,822 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

Raleigh Capital Management held 114,644 shares of Pfizer worth $2.76M as of Q2 2026.
Raleigh Capital Management bought 13,199 Pfizer shares in Q2 2026, an estimated $345K.
Pfizer made up 0.88% of Raleigh Capital Management's portfolio in Q2 2026, its #24 holding.
Raleigh Capital Management first reported a position in Pfizer in Q4 2021 and has held it in 19 quarters since.
Raleigh Capital Management's Pfizer position peaked at $2.85M in Q1 2026.
2,822 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Raleigh Capital Management's 13F filing for Q2 2026, filed 21 Jul 2026.